Contact Person: Michelle Consolazio, Office of the National Coordinator, HHS, 355 E Street SW., Washington, DC 20024, 781–710–0786, Fax: 202–690–6079, email: *michelle.consolazio@hhs.gov.* Please email Michelle Consolazio for up-to-date information on this meeting. A notice in the **Federal Register** about last minute modifications that impact a previously announced advisory committee meeting cannot always be published quickly enough to provide timely notice.

Agenda: The committee will hear reports from its workgroups and updates from ONC and other Federal agencies. ONC intends to make background material available to the public no later than 24 hours prior to the meeting start time. If ONC is unable to post the background material on its Web site prior to the meeting, it will be made publicly available at the location of the advisory committee meeting, and the background material will be posted on ONC's Web site after the meeting, at *http://www.healthit.gov/FACAS/health-it-standards-committee.*

Procedure: Interested persons may present data, information, or views, orally or in writing, on issues pending before the Committee. Written submissions may be made to the contact person prior to the meeting date. Oral comments from the public will be scheduled prior to the lunch break and at the conclusion of each meeting. Time allotted for each presentation will be limited to three minutes. If the number of speakers requesting to comment is greater than can be reasonably accommodated during the scheduled open public session, ONC will take written comments after the meeting.

Persons attending ONC's advisory committee meetings are advised that the agency is not responsible for providing wireless access or access to electrical outlets.

ONC welcomes the attendance of the public at its advisory committee meetings. Seating is limited at the location, and ONC will make every effort to accommodate persons with physical disabilities or special needs. If special accommodations are required, please contact Michelle Consolazio at least seven (7) days in advance of the meeting.

Notice of this meeting is given under the Federal Advisory Committee Act (Pub. L. No. 92–463, 5 U.S.C., App. 2).

Dated: December 6, 2013.

Michelle Consolazio,

FACA Program Director, Office of Policy and Planning, Office of the National Coordinator for Health Information Technology.

[FR Doc. 2013–30102 Filed 12–17–13; 8:45 am]

BILLING CODE 4150–45–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA–2013–N–1204]

Draft Risk Profile on Pathogens and Filth in Spices: Availability; Extension of Comment Period

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice; Extension of comment period.

SUMMARY: The Food and Drug Administration (FDA or we) is extending the comment period for the notice entitled ''Draft Risk Profile on Pathogens and Filth in Spices: Availability'' that appeared in the **Federal Register** of November 4, 2013 (78 FR 66010). In the notice, FDA requested comments that can help improve the data and information used; the analytical analyses employed; and the clarity and transparency of the draft risk profile. We are taking this action in response to a request for an extension to allow interested persons additional time to submit comments, scientific data, and information.

DATES: We are extending the comment period for the draft risk profile. Submit either electronic or written comments by March 3, 2014.

ADDRESSES: Submit electronic comments and scientific data and information to *http://www.regulations.gov.* Submit written comments and scientific data and information to the Division of Dockets Management (HFA–305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.

FOR FURTHER INFORMATION CONTACT: Jane Van Doren, Center for Food Safety and Applied Nutrition (HFS–06), Food and Drug Administration, 5100 Paint Branch Pkwy., College Park, MD 20740, 240–402–2927.

SUPPLEMENTARY INFORMATION:

I. Background

In the **Federal Register** of November 4, 2013 (78 FR 66010), we published a notice entitled ''Draft Risk Profile on Pathogens and Filth in Spices: Availability.'' The notice provided a 60-day comment period for comments that can help improve (1) the data and information used; (2) the analytical analyses employed; and (3) the clarity and transparency of the draft risk profile.

We have received one request for an extension of the comment period for the notice. The request conveyed concern that the current 60-day comment period is not adequate to develop a response to the notice.

We have considered the request and are extending the comment period for the notice for 60 days, until March 3, 2014. We believe that a 60-day extension allows adequate time for interested persons to submit comments, scientific data, and information without significantly delaying the risk profile.

II. Request for Comments

Interested persons may submit either electronic comments regarding this document to *http://www.regulations.gov* or written comments to the Division of Dockets Management (see **ADDRESSES**). It is only necessary to send one set of comments. Identify comments with the docket number found in brackets in the heading of this document. Received comments may be seen in the Division of Dockets Management between 9 a.m. and 4 p.m., Monday through Friday, and will be posted to the docket at *http://www.regulations.gov.*

Dated: December 11, 2013.

Leslie Kux,

Assistant Commissioner for Policy.

[FR Doc. 2013–30055 Filed 12–17–13; 8:45 am]

BILLING CODE 4160–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA–2010–N–0308]

Centers for Medicare and Medicaid Services

[CMS–3180–N3]

Pilot Program for Parallel Review of Medical Products; Extension of the Duration of the Program

AGENCIES: Food and Drug Administration, Centers for Medicare and Medicaid Services, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) and the Centers for Medicare and Medicaid Services (CMS) (the Agencies) are announcing the extension of the ''Pilot Program for Parallel Review of Medical Products.''